185331-04-8

Basic information

• Product Name: 2,4,6-Trioxa-3-phosphaheptan-7-oyl chloride, 1-phenyl-3-(phenylmethoxy)-, 3-oxide
• CAS NO: 185331-04-8
• Molecular Formula: C16H16ClO6P
• Molecular Weight: 370.726
• Mol File: 185331-04-8.mol

Chemical Properties

• CAS DataBase Reference: 2,4,6-Trioxa-3-phosphaheptan-7-oyl chloride, 1-phenyl-3-(phenylmethoxy)-, 3-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,6-Trioxa-3-phosphaheptan-7-oyl chloride, 1-phenyl-3-(phenylmethoxy)-, 3-oxide(185331-04-8)
• EPA Substance Registry System: 2,4,6-Trioxa-3-phosphaheptan-7-oyl chloride, 1-phenyl-3-(phenylmethoxy)-, 3-oxide(185331-04-8)

Safety Data

• Hazardous Substances Data: 185331-04-8(Hazardous Substances Data)

Usage

Uses

Used in Flame Retardant Applications:
2,4,6-Trioxa-3-phosphaheptan-7-oyl chloride, 1-phenyl-3-(phenylmethoxy)-, 3-oxide is used as a flame retardant in various industries for its ability to release phosphoric acid and form a protective layer on the surface of materials, preventing fire spread.
Used in Polymer Industry:
In the polymer industry, 2,4,6-Trioxa-3-phosphaheptan-7-oyl chloride, 1-phenyl-3-(phenylmethoxy)-, 3-oxide is used as a flame retardant additive for enhancing the fire resistance of polymers, ensuring safety and compliance with fire regulations.
Used in Textile Industry:
In the textile industry, 2,4,6-Trioxa-3-phosphaheptan-7-oyl chloride, 1-phenyl-3-(phenylmethoxy)-, 3-oxide is used as a flame retardant finish for textiles, providing fire protection to fabrics used in various applications, such as clothing, upholstery, and curtains.
Used in Electronics Industry:
In the electronics industry, 2,4,6-Trioxa-3-phosphaheptan-7-oyl chloride, 1-phenyl-3-(phenylmethoxy)-, 3-oxide is used as a flame retardant in the manufacturing of electronic components and devices, ensuring safety and compliance with fire regulations.
However, due to the potential toxicity and environmental impact of 2,4,6-Trioxa-3-phosphaheptan-7-oyl chloride, 1-phenyl-3-(phenylmethoxy)-, 3-oxide, its use has become increasingly regulated in recent years, and alternative flame retardants are being developed to minimize the risks associated with its application.

Upstream product

• 50651-75-7 silver dibenzylphosphate 
• 1623-08-1 phosphoric acid dibenzyl ester 
• 935680-47-0 O-({[bis(benzyloxy)phosphoryl]oxy}methyl) S-(sec-butyl) thiocarbonate 

Downstream Products

• 1204307-72-1 (bis(benzyloxy)phosphoryloxy)methyl (5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-yl)methyl(2-(methylsulfonyl)ethyl)carbamate 
• 1204307-71-0 (bis(benzyloxy)phosphoryloxy)methyl (5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-yl)methyl(2-(methylsulfonyl)-1,1-d2-ethyl)carbamate 

Relevant articles and documents

Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530)

A research program to discover solubilizing prodrugs of the HCV NS5A inhibitor pibrentasvir (PIB) identified phosphomethyl analog 2 and trimethyl-lock (TML) prodrug 9. The prodrug moiety is attached to a benzimidazole nitrogen atom via an oxymethyl linkage to allow for rapid and complete release of the drug for absorption following phosphate removal by intestinal alkaline phosphatase. These prodrugs have good hydrolytic stability properties and improved solubility compared to PIB, both in aqueous buffer (pH 7) and FESSIF (pH 5). TML prodrug 9 provided superior in vivo performance, delivering high plasma concentrations of PIB in PK studies conducted in mice, dogs, and monkeys. The improved dissolution properties of these phosphate prodrugs provide them the potential to simplify drug dosage forms for PIB-containing HCV therapy.

PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.

ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF

Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor.

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladd